FDA approves Lundbeck's schizophrenia treatment for teenagers

Following the green light from US health authorities, schizophrenia treatment Rexulti may now be used in patients as young as 13 years in the US.
Photo: Thomas Borberg
Photo: Thomas Borberg
by MIKKEL AABENHUS HEMMINGSEN, translated by daniel pedersen

On Thursday, Lundbeck and partner Otsuk received the green light from the US Food and Drug Administration (FDA) to expand the use of the schizophrenia treatment to include patients aged 13 to 17 years, reports a shared press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading